Pulmonx (LUNG) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

LUNG Pulmonx

Watchlist

8.950
+0.170+1.94%

Close May 22 16:00 ET

347.40MMarket Cap-5811P/E (TTM)

Pre-Market

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Pulmonx Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ReutersMay 6 17:03 ET
Pulmonx Corporation's Financial Outlook: Single-Product Reliance and Market Penetration Hurdles Threaten Profitability
TipRanksMay 5 02:00 ET
Pulmonx Corporation (NASDAQ:LUNG) Q1 2024 Earnings Call Transcript
Yahoo FinanceMay 3 09:43 ET
Pulmonx Is Maintained at Buy by Canaccord Genuity
Pulmonx Is Maintained at Buy by Canaccord Genuity
Dow JonesMay 2 15:26 ET
Canaccord Genuity Maintains Buy on Pulmonx, Lowers Price Target to $15
Canaccord Genuity analyst Jon Young maintains Pulmonx (NASDAQ:LUNG) with a Buy and lowers the price target from $16 to $15.
BenzingaMay 2 15:16 ET
Pulmonx Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 57.23% Canaccord Genuity $16 → $15 Maintains Buy 04/03/2024 78.2% Piper Sandler $17 → $17 Reite
BenzingaMay 2 15:15 ET

Comments

Moomoo AI

Feb 23 08:50

Pulmonx's balance sheet suggests it could easily eliminate its debt. Its revenue growth over the last year indicates potential profitability. However, it had an EBIT loss over the last year, with a negative free cash outflow of US$40m and a US$61m accounting loss.

Is Pulmonx (NASDAQ:LUNG) Using Debt Sensibly?

Moomoo AI

Dec 8, 2023 04:24

Insider sales of Pulmonx shares below the current price, including by Glendon French, could indicate comfort with a lower valuation. A lack of insider purchases in the past year and low insider ownership might suggest a lack of alignment between management and small shareholders.